Atricure Inc (ATRC)

$28.45

-0.34

(-1.18%)▲

Live

Performance

  • $28.17
    $28.84
    $28.45
    downward going graph

    0.98%

    Downside

    Day's Volatility :2.31%

    Upside

    1.34%

    downward going graph
  • $18.94
    $43.00
    $28.45
    downward going graph

    33.43%

    Downside

    52 Weeks Volatility :55.95%

    Upside

    33.84%

    downward going graph

Returns

PeriodAtricure IncSector (Health Care)Index (Russel 2000)
3 Months
20.86%
3.6%
0.0%
6 Months
26.77%
10.2%
0.0%
1 Year
-18.72%
19.6%
0.0%
3 Years
-60.19%
16.8%
-23.0%

Highlights

Market Capitalization
1.4B
Book Value
$9.49
Earnings Per Share (EPS)
-0.86
PEG Ratio
-1.18
Wall Street Target Price
41.13
Profit Margin
-9.33%
Operating Margin TTM
-6.17%
Return On Assets TTM
-3.65%
Return On Equity TTM
-8.68%
Revenue TTM
430.0M
Revenue Per Share TTM
9.22
Quarterly Revenue Growth YOY
15.2%
Gross Profit TTM
245.9M
EBITDA
-17.5M
Diluted Eps TTM
-0.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.79
EPS Estimate Next Year
-0.62
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Atricure Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
1
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 44.57%

Current $28.45
Target $41.13

Company Financials

FY18Y/Y Change
Revenue
201.6M
↑ 15.4%
Net Income
-21.1M
↓ 21.4%
Net Profit Margin
-10.48%
↑ 4.91%
FY19Y/Y Change
Revenue
230.8M
↑ 14.47%
Net Income
-35.2M
↑ 66.5%
Net Profit Margin
-15.25%
↓ 4.77%
FY20Y/Y Change
Revenue
206.5M
↓ 10.52%
Net Income
-48.2M
↑ 36.83%
Net Profit Margin
-23.32%
↓ 8.07%
FY21Y/Y Change
Revenue
274.3M
↑ 32.83%
Net Income
50.2M
↓ 204.24%
Net Profit Margin
18.3%
↑ 41.62%
FY22Y/Y Change
Revenue
330.4M
↑ 20.43%
Net Income
-46.5M
↓ 192.56%
Net Profit Margin
-14.06%
↓ 32.36%
FY23Y/Y Change
Revenue
399.2M
↑ 20.84%
Net Income
-30.4M
↓ 34.49%
Net Profit Margin
-7.62%
↑ 6.44%
Q1 FY23Q/Q Change
Revenue
93.5M
↑ 6.21%
Net Income
-6.5M
↑ 55.3%
Net Profit Margin
-6.93%
↓ 2.19%
Q2 FY23Q/Q Change
Revenue
100.9M
↑ 7.94%
Net Income
-5.1M
↓ 20.97%
Net Profit Margin
-5.07%
↑ 1.86%
Q3 FY23Q/Q Change
Revenue
98.3M
↓ 2.6%
Net Income
-9.1M
↑ 76.92%
Net Profit Margin
-9.21%
↓ 4.14%
Q4 FY23Q/Q Change
Revenue
106.5M
↑ 8.4%
Net Income
-9.8M
↑ 8.11%
Net Profit Margin
-9.19%
↑ 0.02%
Q1 FY24Q/Q Change
Revenue
108.9M
↑ 2.17%
Net Income
-13.3M
↑ 35.55%
Net Profit Margin
-12.19%
↓ 3.0%
Q2 FY24Q/Q Change
Revenue
116.3M
↑ 6.81%
Net Income
-8.0M
↓ 39.65%
Net Profit Margin
-6.89%
↑ 5.3%
FY18Y/Y Change
Total Assets
356.8M
↑ 33.27%
Total Liabilities
107.4M
↑ 0.79%
FY19Y/Y Change
Total Assets
557.9M
↑ 56.37%
Total Liabilities
310.5M
↑ 189.2%
FY20Y/Y Change
Total Assets
714.5M
↑ 28.08%
Total Liabilities
302.1M
↓ 2.7%
FY21Y/Y Change
Total Assets
615.3M
↓ 13.89%
Total Liabilities
131.6M
↓ 56.46%
FY22Y/Y Change
Total Assets
585.4M
↓ 4.85%
Total Liabilities
128.7M
↓ 2.18%
FY23Y/Y Change
Total Assets
613.9M
↑ 4.87%
Total Liabilities
147.8M
↑ 14.82%
Q1 FY23Q/Q Change
Total Assets
583.1M
↓ 0.4%
Total Liabilities
128.3M
↓ 0.34%
Q2 FY23Q/Q Change
Total Assets
594.2M
↑ 1.9%
Total Liabilities
131.7M
↑ 2.72%
Q3 FY23Q/Q Change
Total Assets
600.3M
↑ 1.03%
Total Liabilities
137.4M
↑ 4.32%
Q4 FY23Q/Q Change
Total Assets
613.9M
↑ 2.28%
Total Liabilities
147.8M
↑ 7.51%
Q1 FY24Q/Q Change
Total Assets
591.6M
↓ 3.63%
Total Liabilities
135.3M
↓ 8.42%
Q2 FY24Q/Q Change
Total Assets
597.3M
↑ 0.95%
Total Liabilities
135.2M
↓ 0.09%
FY18Y/Y Change
Operating Cash Flow
-4.2M
↓ 53.37%
Investing Cash Flow
-85.4M
↓ 2370.78%
Financing Cash Flow
100.2M
↑ 3529.57%
FY19Y/Y Change
Operating Cash Flow
-15.8M
↑ 279.07%
Investing Cash Flow
-2.1M
↓ 97.49%
Financing Cash Flow
14.4M
↓ 85.65%
FY20Y/Y Change
Operating Cash Flow
-19.9M
↑ 25.67%
Investing Cash Flow
-156.2M
↑ 7175.17%
Financing Cash Flow
189.4M
↑ 1217.69%
FY21Y/Y Change
Operating Cash Flow
-13.8M
↓ 30.65%
Investing Cash Flow
23.5M
↓ 115.05%
Financing Cash Flow
-7.6M
↓ 104.04%
FY22Y/Y Change
Operating Cash Flow
-22.1M
↑ 60.67%
Investing Cash Flow
44.0M
↑ 87.23%
Financing Cash Flow
-7.1M
↓ 7.63%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 8967.39%
Investing Cash Flow
28.8M
↑ 311.5%
Financing Cash Flow
-5.5M
↓ 378.36%
Q2 FY23Q/Q Change
Operating Cash Flow
3.0M
↓ 173.82%
Investing Cash Flow
-16.1M
↓ 155.81%
Financing Cash Flow
3.0M
↓ 154.27%

Technicals Summary

Sell

Neutral

Buy

Atricure Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atricure Inc
Atricure Inc
-0.9%
26.77%
-18.72%
-60.19%
8.81%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
6.56%
41.26%
91.18%
53.45%
177.85%
Resmed Inc.
Resmed Inc.
-2.51%
33.07%
63.68%
-8.76%
83.88%
Becton, Dickinson And Company
Becton, Dickinson And Company
3.84%
4.22%
-4.76%
-1.1%
-4.07%
Alcon Ag
Alcon Ag
-2.89%
18.03%
30.76%
16.68%
62.63%
Cooper Companies Inc., The
Cooper Companies Inc., The
-1.41%
20.24%
-66.42%
5.22%
50.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atricure Inc
Atricure Inc
34.48
NA
-1.18
-0.79
-0.09
-0.04
NA
9.49
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
81.54
81.54
4.08
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
34.67
34.67
2.0
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
48.07
48.07
1.11
13.11
0.06
0.03
0.02
89.5
Alcon Ag
Alcon Ag
42.58
42.58
3.58
3.06
0.05
0.03
0.0
42.35
Cooper Companies Inc., The
Cooper Companies Inc., The
59.32
59.32
11.0
3.66
0.05
0.03
NA
39.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atricure Inc
Atricure Inc
Buy
$1.4B
8.81%
34.48
-9.33%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$168.3B
177.85%
81.54
27.65%
Resmed Inc.
Resmed Inc.
Buy
$35.2B
83.88%
34.67
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$69.5B
-4.07%
48.07
7.13%
Alcon Ag
Alcon Ag
Buy
$46.6B
62.63%
42.58
11.44%
Cooper Companies Inc., The
Cooper Companies Inc., The
Buy
$21.3B
50.71%
59.32
9.45%

Insights on Atricure Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 98.29M → 116.26M (in $), with an average increase of 5.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -13.26M → -8.00M (in $), with an average increase of 65.7% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 95.3% return, outperforming this stock by 114.3%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 53.4% return, outperforming this stock by 113.6%

Institutional Holdings

  • Vanguard Group Inc

    9.49%

  • BlackRock Inc

    9.48%

  • AllianceBernstein L.P.

    8.63%

  • Champlain Investment Partners, LLC

    5.49%

  • FMR Inc

    4.34%

  • Macquarie Group Ltd

    4.10%

Company Information

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.

Organization
Atricure Inc
Employees
1200
CEO
Mr. Michael H. Carrel
Industry
Health Technology

Discover More

FAQs